Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 12:29PM ET
7.02
Dollar change
-0.23
Percentage change
-3.17
%
Index- P/E- EPS (ttm)-9.87 Insider Own18.26% Shs Outstand2.72M Perf Week-6.02%
Market Cap19.09M Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float2.23M Perf Month-32.95%
Income-21.69M PEG- EPS next Q-0.47 Inst Own101.22% Short Float0.57% Perf Quarter31.21%
Sales0.01M P/S1909.44 EPS this Y63.85% Inst Trans- Short Ratio0.14 Perf Half Y104.07%
Book/sh4.22 P/B1.66 EPS next Y62.98% ROA-186.85% Short Interest0.01M Perf Year75.79%
Cash/sh5.21 P/C1.35 EPS next 5Y- ROE-267.59% 52W Range1.86 - 10.70 Perf YTD117.34%
Dividend Est.- P/FCF- EPS past 5Y66.41% ROI-187.61% 52W High-34.39% Beta0.92
Dividend TTM- Quick Ratio4.18 Sales past 5Y748.79% Gross Margin-4700.00% 52W Low277.42% ATR (14)0.62
Dividend Ex-Date- Current Ratio4.18 EPS Y/Y TTM59.77% Oper. Margin-308571.43% RSI (14)39.54 Volatility6.48% 8.28%
Employees18 Debt/Eq0.03 Sales Y/Y TTM-89.71% Profit Margin-309885.71% Recom1.00 Target Price23.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q38.78% Payout- Rel Volume0.27 Prev Close7.25
Sales Surprise- EPS Surprise-110.26% Sales Q/Q-100.00% EarningsMay 13 BMO Avg Volume91.65K Price7.02
SMA20-10.87% SMA50-8.49% SMA20052.73% Trades Volume12,357 Change-3.17%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Initiated Piper Sandler Overweight $30
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
May-13-24 02:53PM
08:15AM
May-01-24 08:00AM
Apr-18-24 07:30AM
07:00AM
08:00AM Loading…
Apr-09-24 08:00AM
Mar-24-24 07:55AM
Feb-13-24 08:00AM
Nov-30-23 07:00AM
Nov-17-23 08:00AM
Nov-13-23 08:00AM
Sep-21-23 08:00AM
Aug-21-23 09:02PM
Aug-18-23 09:02PM
Aug-11-23 01:00PM
10:30PM Loading…
Aug-08-23 10:30PM
Jul-25-23 01:00PM
Jun-26-23 08:00AM
May-15-23 08:00AM
May-08-23 08:05AM
08:00AM
Feb-13-23 08:00AM
Jan-23-23 09:48AM
Nov-10-22 08:00AM
Sep-16-22 08:42AM
Sep-12-22 10:06PM
Sep-02-22 08:00AM
Jul-15-22 06:52AM
May-16-22 08:15AM
Feb-14-22 08:00AM
12:53PM Loading…
Jan-18-22 12:53PM
Jan-17-22 09:30AM
Nov-27-21 06:54AM
Nov-15-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 03:58PM
Sep-08-21 08:10AM
08:05AM
08:00AM
May-31-21 01:54AM
Apr-27-21 09:55PM
04:44PM
Mar-23-21 12:18PM
07:24AM
07:09AM
Feb-24-21 09:26AM
08:29AM
Dec-07-20 02:33PM
Dec-02-20 12:06AM
Oct-06-20 04:05PM
Oct-02-20 09:05AM
Sep-23-20 04:54PM
Sep-01-20 08:15AM
Jul-08-20 08:00AM
Apr-20-20 06:49AM
Apr-15-20 08:52AM
Apr-14-20 09:28PM
Mar-30-20 10:09AM
Mar-26-20 09:44AM
Feb-27-20 06:18PM
Jan-31-20 08:08AM
Nov-27-19 08:00AM
Nov-17-19 07:02PM
Nov-15-19 07:00AM
Oct-31-19 08:30AM
Sep-30-19 09:24AM
Sep-19-19 09:15AM
Sep-16-19 08:00AM
Sep-15-19 09:49PM
Jul-31-19 08:30AM
Jul-11-19 11:34PM
Jun-06-19 08:09AM
May-08-19 08:01PM
Mar-06-19 09:52PM
Jan-29-19 09:46PM
Dec-21-18 10:10AM
Nov-23-18 12:01AM
Nov-15-18 07:35AM
Sep-19-18 08:00AM
Jul-14-18 02:02PM
Jul-10-18 05:15PM
08:10AM
07:30AM
Jul-09-18 11:04AM
Jul-08-18 08:59PM
May-31-18 08:00AM
May-15-18 08:00AM
May-03-18 08:00AM
Apr-24-18 08:00AM
Mar-05-18 08:00AM
Feb-22-18 08:30AM
Jan-23-18 04:17PM
Jan-16-18 08:00AM
Nov-27-17 09:30AM
08:00AM
Oct-18-17 07:45AM
Sep-05-17 02:54PM
Sep-01-17 04:00PM
Aug-08-17 08:30AM
Apr-05-17 07:30AM
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.